Kornimate/medical-research-clean huggingface dataset:
skin rash study before chemotherapy in colorectal & head and neck cancer patients

Conditions: Colorectal Cancer; Head and Neck Cancer

Summary: the purpose of this study is to determine if using preventive treatments such as doxycycline (an anti-biotic) capsules, sunscreen with spf 30, hydrocortisone 1% cream and a moisturizer will help to reduce the incidence and severity of the skin rash associated with cetuximab (erbitux®) when compared to receiving standard care for the treatment of skin rash.

of the 100 subjects who will participate in this study, 50 will be in the extensive treatment group and 50 will be in the standard care group. subjects in the extensive treatment group will use doxycycline capsule, 100 mg, taken twice daily, sunscreen spf 30 or higher, moisturizer applied to the face, hands, feet, neck, back, and chest each morning after sunscreen, hydrocortisone 1% cream applied to the face, hands, feet, neck, back, and chest each evening. subjects will start taking the capsule and applying the creams three days prior to beginning cetuximab therapy. they will continue this regimen of taking the capsule and applying the creams for 8 weeks. if they develop severe skin rash as a result of cetuximab therapy, the study doctor may decide to reduce the amount of the dose of cetuximab that they receive or prescribe other medicines according to standard treatment recommendations, just as he/she would if the subject was not participating in this study. subjects will be monitored at enrollment, 3 weeks into cetuximab treatment and at the end of cetuximab treatment for adherence, side effects and quality of life. the standard care group will not receive preventive treatment, but they will be allowed to use sunscreen and moisturizer if desired. they, too, will be monitored at enrollment, 3 weeks into cetuximab treatment and at the end of cetuximab treatment for adherence, side effects and quality of life. if a subject is assigned to this group and they develop a severe skin rash, the study doctor will treat their rash according to standard treatment recommendations, which may include hydrocortisone 1% cream, doxycycline capsules or other medications. there will be a follow-up period for both extensive treatment and standard care groups. at 6 months, 12 months, 18 months and 24 months, after the end of the subject's 8 week study treatment period, they will be contacted by telephone or discussed during their routine clinic visit.

Eligibility criteria:
inclusion criteria: 1. age greater than or equal to 18 years 2. diagnosis of colorectal or head and neck cancer 3. receipt of at least one dose of cetuximab during the study time period exclusion criteria: 1. prior cetuximab treatment within the 6 months of study initiation 2. current treatment with tyrosine kinase inhibitors 3. patients who are pregnant or incarcerated
predea study, prevention in emergency / acceptance departments: the case of hepatic steatosis

Conditions: Hepatic Steatosis

Summary: our study aims to evaluate whether the emergency department (ps) can support the health system to improve the prevention and management of chronic inflammatory diseases and ensure actions aimed at screening, raising awareness and informing the population. specifically, the determination of the prevalence of a widely diffused pathology such as fatty liver disease aims to be the precursor of future pilot studies aimed at evaluating the advantages and critical issues of the ps as a prevention tool.


Eligibility criteria:
inclusion criteria: * patients over 18 * patients admitted to emergency department in white or green code exclusion criteria: * patients under 18 * patients admitted to emergency department in yellow or red code
the feasibility of a radiological score based on ct signs for recognizing salvageable bowel in acute mesenteric ischemia

Conditions: Acute Mesenteric Ischemia

Summary: computed tomography (ct) is the standard modality for scanning patients with critical acute abdominal conditions, including suspected acute mesenteric ischemia (ami). ct imaging can potentially differentiate between reversible and irreversible ischaemic damage of the bowel. this moment is pivotal in selecting the treatment strategy for ami - in the absence of irreversible damage; reperfusion therapy can preserve intestinal viability, thereby avoiding the need for bowel resection. the present study tests the hypothesis that combining several symptoms may enhance the diagnostic performance of ct scanning in detecting salvageable bowel in patients with ami. this study is an ancillary component of the amesi study (clinical trials: nct05218863) - a prospective, multicentre observational study aimed at identifying the incidence and describing the outcomes of acute mesenteric ischemia (ami) in adult hospitalized patients. the ultimate purpose of the present study is to create a computed tomography-based radiological score for the assessment of bowel viability in patients with ami.


Eligibility criteria:
inclusion criteria: * participant in amesi study * confirmed or suspected acute mesenteric ischaemia * ct scan of the entire abdominal cavity / full body using intravenous contrast media is available exclusion criteria: * scans without the use of an intravenous contrast media or those covering only a partial area of the abdomen will be excluded.
compression treatment effects on complications and healing of achilles tendon rupture

Conditions: Rupture; Venous Thromboembolism; Venous Thrombosis; Surgical Wound Infection

Summary: this prospective randomized study aims to determine whether intermittent pneumatic compression (ipc), 75 patients, beneath functional bracing compared to treatment-as-usual in plaster cast, 75 patients, can reduce the venous thromboembolism (vte) incidence and promote healing of sutured acute achilles tendon ruptures. at two weeks post surgery, the ipc intervention will be ended and both patient groups will be immobilized in an orthosis until follow-up at six weeks. the endpoint of the first part of the study is vte events. the primary outcome will be the dvt-incidence at two weeks, assessed using screening compression duplex ultrasound (cdu) by two ultrasonographers masked to the treatment allocation. secondary outcome will be the dvt-incidence at 6 weeks. 1) deep vein thrombosis (dvt) detected by cdu , 2) isolated calf muscle vein thrombosis (icmvt) detected by cdu, 3) symptomatic dvt or icmvt detected by cdu, 4) symptomatic pulmonary embolism detected by computer tomography. the endpoint of the second part of the study is tendon healing quantified at 2 weeks by microdialysis followed by quantification of markers for tendon repair. the endpoint of the third part of the study is the functional outcome of the patients at one year post-operatively using four reliable and valid scores, i.e. the achilles tendon total rupture score (atrs), physical activity scale (pas), foot and ankle outcome score (faos) and euroqol group's questionnaire (eq-5d) as well as the validated heel-rise test.

the incidence of dvt after achilles tendon rupture is as high as 30-40% and patients exhibit a prolonged healing process with variable outcome. moreover, it has been demonstrated that low molecular weight heparin had no effect on preventing dvt after achilles tendon surgery. whether intermittent pneumatic compression (ipc) can prevent dvts and improve healing after achilles tendon rupture has to our knowledge not been tested before.

Eligibility criteria:
inclusion criteria: * achilles tendon rupture operated on within 96 hours of diagnose. exclusion criteria: 1. inability or refusal to give informed consent for participation in the study 2. ongoing treatment with anticoagulant therapy 3. inability to comply with the study instructions 4. known kidney disorder 5. heart failure with pitting oedema 6. thrombophlebitis 7. recent thromboembolic event (during the preceding 3 months) 8. recent surgery (during the preceding month) 9. presence of known malignancy 10. current bleeding disorder 11. pregnancy

Keywords: achilles tendon immobilization wound healing intermittent pneumatic compression ultrasonography microdialysis
an observational study of pruritus amongst hemodialysis patients

Conditions: Pruritus; Kidney Failure, Chronic; Hemodialysis; Chronic Disease

Summary: the purpose of this observational study is to better understand the natural history/natural course of uremic pruritus (up) - itching associated with chronic kidney disease(ckd). during the lifetime of a ckd dialysis patient, up tends to be a prolonged, frequent, and an intense itch that is known to impair the patient's quality of life (qol), including sleep and mood. the study will follow hemodialysis (hd) patients longitudinally to characterize their pruritus over time. the study will quantify and characterize up and assess change over time; collect data on conditions that may be affected by up such as sleep, mood, socialization and overall quality of life; collect data on use of medications, particularly anti-pruritic treatments, sleep aids, and medications for depression and anxiety; and collect data on medical resource use, particularly hospitalizations for treatment of skin and other infections over the duration of the study.


Eligibility criteria:
inclusion criteria: * patients aged ≥ 18 years; * patients receiving chronic hemodialysis 3 or more times per week; * patients who have "mild", "moderate" or "severe" pruritus; * "mild" pruritus is defined as a nighttime or daytime worst itch intensity vas \>10 mm and \< 40 mm at screening and a combined daytime and nighttime kawashima itch severity score of \< 2; * "moderate" pruritus is defined as a nighttime or daytime worst itch intensity vas \>10 mm and \< 40 mm at screening and a combined daytime and nighttime kawashima itch severity score of ≥ 3; * "severe" pruritus is defined as a nighttime or daytime worst itch intensity vas of ≥ 40 mm at screening and a combined daytime and nighttime kawashima itch severity score of ≥ 3; * patients who are able to understand and complete questionnaires written in english; * patients who are expected to continue to dialyze at the present dialysis unit for the duration of the study. exclusion criteria: * patients who have pruritus attributed to causes other than chronic kidney disease (ckd) or the direct consequences of ckd (i.e., hyperparathyroidism, circulating "uremic toxins"); * patients who have had significant alteration in their dialysis regimen within the 2 weeks prior to screening (or those for whom such changes are anticipated during the study) are excluded. a "significant alteration" is defined as: * a change in the type of hemodialysis filter; * an increase or decrease in total duration of dialysis prescribed of \> 1 hour/week; * a change in the site or type of venous access for dialysis; * an increase or decrease in prescribed blood flow of \>100 ml/min; * patients who are unwilling to comply with the study protocol. test product, dose, mode of administration and duration of treatment
the effect of the emotional freedom technique on students

Conditions: Coping Skills; Anxiety; Complementary Therapies; Stress

Summary: introduction: the interruption of education within the scope of quarantine and isolation methods during the pandemic process has caused nursing students studying in clinical practice areas to be away from the clinic for a long time. this situation not only affected the anxiety levels of nursing students, but also caused them to feel inadequate and to experience stress. purpose: the aim of this study is to investigate the effect of emotional freedom technique on nursing students' styles of coping with anxiety and stress. method:in this experimentally designed study with pretest-posttest control group, freedom of emotion technique will be applied to the experimental group for 4 sessions. in the pre-implementation phase and after the emotional freedom technique session, the state anxiety scale, coping styles scale, and subjective discomfort level scale will be applied.

emotional freedom technique (eft), a type of energy that has been applied recently, is a technique applied by touching meridian points to provide anxiety, depression, burnout, stress management, and desensitization to fear. the basic principle of eft is to send activation and deactivation signals to the brain by stimulating points on the skin with different electrical properties, usually by touching them. the findings obtained from the studies show that this technique, which is a psychotherapeutic technique and provides cognitive restructuring, has statistically significant improvements at the rate of 98% in the management of psychological problems. studies show that this approach is positive in coping with stress when considered in a wide range. church et al. revealed that self-administered eft provides significant improvements in anxiety, depression, pain and craving scores. a large therapeutic effect for eft was reported in a meta-analysis of 14 randomized controlled trials using the eft technique for anxiety disorders. in the studies, it was aimed to apply this application, which has proven positive results, to apply the emotional freedom technique in order to reduce the anxiety experienced by the students due to the reasons such as distance education and clinical education during the covid-19 pandemic process and to enable them to cope with stress. research questions this study aims to address the following research questions: what are the anxiety levels of the students who applied the emotional freedom technique (eft)? what are the stress coping styles of the students who applied emotional freedom technique (eft)?

Eligibility criteria:
inclusion criteria: * not receiving any psychiatric diagnosis, * not receiving any therapy for coping with anxiety and stress, * not applying emotional freedom technique before, * not being in the covid-19 diagnosis, treatment care process, and * participating in the study determined to be voluntary. exclusion criteria: -not participating in any of the eft sessions and being diagnosed with covid-19.
interest of sflt1/plgf ratio at obstetric emergencies

Conditions: Suspected Placental Dysfunction, Ruled Out; Pregnancy Complications; Pre-Eclampsia

Summary: in patients with suspected placental vascular disease who do not require hospitalization, the use of the sflt-1 (soluble fms like tyrosin-kinase-1)/plgf (placental growth factor)/ assay can most likely help teams to define the best possible management.

preeclampsia is a serious obstetric condition, affecting 2 to 5% of pregnancies and associated with maternal hypertension and renal dysfunction. it is a constant concern of obstetrical teams in the pre and post partum period. in case of diagnosis in the emergency unit, patients are usually hospitalized. however, in the case of a diagnosis of preeclampsia has been invalidated, but in presence of isolated or frustrated clinical functional signs, in the case of a history of placental vascular pathology, obstetric teams implement surveillance strategies that are binding on the patients. the sflt-1/ plgf assay has a high negative predictive value for the coming week. the use in clinical practice of these two biomarkers in the indication of negative prediction at one week could help teams in their management but the interest of this use needs to be evaluated.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * pregnant patients term ≥ at 24 weeks of amenorrhoea (sa), * management in obstetrical emergencies and at the centre hopsitalier intercommunal (chi) de créteil functional exploration center, with prescription of a vascular-renal check-up (bvr) ((proteinuria/creatinuria ratio, blood count, platelets, blood ionogram, creatinemia, transaminases (asat, alat), haptoglobulinemia, lactate dehydrogenase (ldh), tp). * presenting either one of the following isolated or associated clinical parameters: * hypertension * urinary tape proteinuria * functional signs of hypertension (headaches, phosphenes, accouphènes) * live osteotendinous reflexes * epigastric pains * weight gain, lower limb edema, facial edema * oliguria * vomiting * or one of the following isolated or associated ultrasound parameters: * fetal hypotrophy, fetal growth deflection * fetal doppler abnormalities (umbilical doppler, cerebral doppler) * ooligo-anamnios with intact membranes * patient who has been informed and has given her oral non-opposition exclusion criteria: * diagnosis of preeclampsia * refusal of the patient * patient whose symptomatology (clinical or paraclinical) leads to a decision to be hospitalized * age \< 18 years old * non-affiliation to the general social security system
what are the brakes and levers of physical activity practice for patients with chronic lower back pain?

Conditions: Non-specific Chronic Lower Back Pain

Summary: non-specific chronic lower back pain is a common pathology which is a real public health problem. around 84% of the population could have non-specific chronic lower back pain at least once in their lives and 8% of that non-specific lower back pain could become chronical (pain that would last at least 3 months). this proportion of patients represents 85% of the costs related to this pathology. physical activity practice is involved in medical care for plenty of chronical diseases and particularly for chronic lower back pain. in 2003, world health organization pointed out the poor adhesion of patients with chronical diseases to medical prescriptions and the after-effects it could have on illness evolution. therefore, adhesion to physical activity practice for patients with chronic lower back pain is one of the most challenging matters for medical teams. the aim of this study was to identify the brakes and levers of physical activity practice for these patients. sixteen individual interviews and four focus groups have been carried out on patients with chronic lower back pain who were taken care of either by a rachis functional restoration program or by primary care.

non-specific chronic lower back pain is a common pathology which is a real public health problem. around 84% of the population could have non-specific chronic lower back pain at least once in their lives and 8% of that non-specific lower back pain could become chronical (pain that would last at least 3 months). this proportion of patients represents 85% of the costs related to this pathology. physical activity practice is involved in medical care for plenty of chronical diseases and particularly for chronic lower back pain. in 2003, world health organization pointed out the poor adhesion of patients with chronical diseases to medical prescriptions and the after-effects it could have on illness evolution. therefore, adhesion to physical activity practice for patients with chronic lower back pain is one of the most challenging matters for medical teams. the aim of this study was to identify the brakes and levers of physical activity practice for these patients. sixteen individual interviews and four focus groups have been carried out on patients with chronic lower back pain who were taken care of either by a rachis functional restoration program or by primary care.

Eligibility criteria:
inclusion criteria: * male or female who are at least 18 years old * patients with non-specific chronic lower back pain exclusion criteria: * mental or physical disabilities incompatible with focus groups/individual interviews and filling out questionnaires. * inability to understand or speak french properly * symptomatic lower back pain

Keywords: non-specific chronic lower back pain physical activity self-exercises brakes levers adhesion self-care
evaluation of renal function, efficacy, and safety when switching from tenofovir/emtricitabine plus a protease inhibitor/ritonavir, to a combination of raltegravir (mk-0518) plus nevirapine plus lamivudine in hiv-1 participants with suppressed viremia and impaired renal function (mk-0518-284)

Conditions: HIV Infections

Summary: to evaluate changes in renal function, efficacy, and safety when switching from a combination of tenofovir/emtricitabine (tdf/ftc) plus a protease inhibitor/ritonavir (pi/r) to a combination of raltegravir (mk-0518) plus nevirapine plus lamivudine in human immunodeficiency virus (hiv)-1 infected participants with suppressed viremia and impaired renal function.


Eligibility criteria:
inclusion criteria: * male, or non-pregnant, non-breastfeeding female * no previous history of virological failure * no previous exposure to non-nucleoside reverse transcriptase inhibitors or integrase inhibitors * no previous history of intolerance to lamivudine * at least 2 documented plasma hiv-1 rna \ 50 copies/ml in the 12 months before screening * receiving the same protease inhibitor/ritonavir plus tenofovir/emtricitabine combination for at least the 6 months before screening * has no major international antiviral society (ias)-usa mutations on genotype testing performed before starting antiretroviral treatment * sexually-active participants and their partners of child-bearing potential agree to use a medically acceptable method of contraception from 2 weeks before day 1 and for at least 6 months after the last dose of study drug (postmenopausal women are not required to use contraception; sexually-active male participants with a female partner of child-bearing potential must provide written informed consent to information regarding any pregnancy) exclusion criteria: * positive for hepatitis b surface antigen (hbsag+) or anticipated need for hepatitis c virus treatment * liver cirrhosis * has a history of diabetes mellitus, defined as initiation of antidiabetic treatment or verification of diabetes in a case report form * has any cancer, excluding stable kaposi sarcoma * allergy or sensitivity to the investigational product or excipients * female participant who is nursing * female participant who is pregnant or intends to become pregnant * has an active acquired immunodeficiency syndrome (aids)-defining event except stable kaposi sarcoma or hiv wasting syndrome * received any investigational drug within 30 days before screening * participated in any other clinical trial within 30 days before signing informed consent for the current trial